Skip to main content
OpenTrials
Completed

NCT Number: NCT00733200

Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

The investigators conducted a prospective study to determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in 138 patients with hilar cholangiocarcinoma. In selected patients, minor liver resection was a good treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cholangiocarcinoma Adenocarcinoma Carcinoma Hepatectomy Neoplasms Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Surgical Treatment

Age range

26 year–72 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Objective: To determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in patients with hilar cholangiocarcinoma (HC).

Summary Background Data: For HC treated with hepatectomy, the extent of liver resection remains controversial despite extensive studies.

Methods: From January 2000 to December 2007, we prospectively studied patients who received surgical treatment for HC. Of the 187 patients who were surgically treated, 138 (73.8%) underwent resection with a curative intent. Minor hepatectomy was carried out in 93 patients who had Bismuth-Corlette types I, II and III HC without hepatic artery/portal vein invasion; and major hepatectomy in 45 patients who had type III HC with hepatic artery/portal vein invasion, or type IV HC.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Criteria for resectability were absence of peritoneal or liver metastases, tumor extension to beyond secondary biliary branches bilaterally, tumor extension to secondary portal venous branches bilaterally

Exclusion criteria

  • not in accordance with the above criteria

Treatment and study plan

Minor or Major Liver Resection

Procedure

Primary outcomes

  1. On multivariate analysis, prognostic factors significantly impacted on long-term survival were UICC tumor stage and histopathologic grade.

Sponsors and collaborators

Lead sponsor

Huazhong University of Science and Technology

Other

Collaborators

  • Hepatic Surgery Clinical Research Centre of Hubei, China
  • Ministry of Health, China

Registry information

Important dates

First posted
Aug 12, 2008
Registry last updated
Dec 11, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.